Find a Doctor

BY
Areas of Expertise

Benoit M. You

Université Claude Bernard Lyon 1
Male

Bio

Benoit You is in Lyon, France. They have been an author on 128 peer reviewed articles and participated in 11 clinical trials in the past 15 years.

Areas of Expertise

Contact

Lyon, FR

Latest Advances

Latest Advance
Study
  • Condition: Germline BRCA-Mutated Metastatic Breast Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Olaparib and Durvalumab
  • Number of Patients: 34
  • Published —
The purpose of the study was to assess the safety and activity of Olaparib in combination with Durvalumab in patients with germline BRCA1-mutated or BRCA1-mutated metastatic breast cancer.
Latest Advance
Study
  • Condition: Cancer with Mild to Moderate Hepatic Impairment
  • Journal: The Journal of pharmacology and experimental therapeutics
  • Treatment Used: Osimertinib
  • Number of Patients: 22
  • Published —
This study tested the safety and efficacy of using osimertinib to treat cancer patients with mild to moderate hepatic impairment.
Latest Advance
Study
  • Condition: Ovarian cancer
  • Journal: Gynecologic oncology
  • Treatment Used: Non-pegylated liposomal doxorubicin
  • Number of Patients: 87
  • Published —
This study assessed the effectiveness and tolerance of the chemotherapy drug, non-pegylated liposomal doxorubicin (NPLD), in comparison to the standard treatment of pegylated liposomal doxorubicin as a treatment for ovarian cancer. Pegylation refers to the addition of a compound to the chemical structure of this drug, often to reduce the chance that the patient's immune system would respond against the treatment and, in some cases, improve the ability for the drug to dissolve in water-based solutions.

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Behavioral
  • Participants: 100
  • Start Date: January 1, 2021
Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab.
Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Procedure, Drug
  • Participants: 132
  • Start Date: November 30, 2019
Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Other
  • Participants: 2000
  • Start Date: July 2019
A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 410
  • Start Date: December 4, 2018
Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 404
  • Start Date: September 25, 2018
A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 132
  • Start Date: April 24, 2018
Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Behavioral
  • Participants: 184
  • Start Date: March 29, 2018
ADOPT-PRESTAGE: Randomized Controlled Trial on Acceptability, Diffusion and Impact on Treatment Adherence and Persistence of the PRESTAGE Program (Program for Education and Support for Oral Cancer Treatments in the Elderly) - Randomized Controlled Study Evaluating the Impact of the Program PRESTAGE
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug, Biological
  • Participants: 66
  • Start Date: January 3, 2017
A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions.
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 72
  • Start Date: April 2016
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Combination Product
  • Participants: 560
  • Start Date: March 2014
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Genetic
  • Participants: 10000
  • Start Date: February 2013
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

All Publications
View All

Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Reply to J. R. Lurain et al.
Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.

Contact

Lyon, FR

Insurance

Contact them to find out if they accept your insurance plan.